Epilepsia Open is a premier open access journal dedicated to advancing the field of neurology, particularly in the area of epilepsy research and clinical practice. Published by WILEY since 2016, this journal aims to provide a platform for high-quality, peer-reviewed research that fosters collaboration among researchers, clinicians, and educators within the global neurological community. With an impactful presence in the field, it holds a prestigious Q2 ranking in both Neurology and Clinical Neurology categories as of 2023 and has been recognized for its contributions to the understanding of epilepsy through its diverse range of articles, reviews, and clinical studies. Researchers and practitioners can benefit from the journal's open access model, which ensures that valuable findings are readily available to the public, promoting further developments in treatment and care. The journal's significant visibility is reflected in its Scopus rankings, where it ranks in the top half of peer-reviewed journals in both Neurology and Neuroscience categories. For those committed to improving the lives of those affected by epilepsy, Epilepsia Open represents a crucial resource for cutting-edge knowledge and innovative practices.

REVUE NEUROLOGIQUE, published by MASSON EDITEUR, is a prestigious academic journal that plays an essential role in the field of neurology. With a rich history spanning from 1946 to the present, this journal focuses on both foundational and clinical aspects of neurology, underscoring its significance within the medical community. Holding an impressive Q2 ranking in both general and clinical neurology categories as of 2023, REVUE NEUROLOGIQUE is recognized for its contribution to advancing neurological science, as evidenced by its Scopus rankings, with a notable position in the 62nd percentile for clinical neurology. The journal fosters an environment for rigorous research and is instrumental for professionals and scholars aiming to stay abreast of the latest developments in neurological disorders and treatments. Although it is not an open-access publication, it offers a wealth of vital research through its issues, appealing to those engaged in both clinical practice and academic research in neurology.

EPILEPSIA is a premier academic journal published by Wiley, with a storied history dating back to 1909, making it a cornerstone in the field of epilepsy research and neurology. With an impressive impact factor reflecting its robust contribution to the academic community, EPILEPSIA is categorized in the top quartile (Q1) in both neurology and clinical neurology as of 2023, underscoring its significance and prestige. The journal is ranked #15 out of 192 in Neuroscience & Neurology and #34 out of 400 in Medicine & Neurology (clinical) within Scopus, indicating its essential role in advancing knowledge and treatments related to epilepsy. Researchers and clinicians are encouraged to contribute groundbreaking studies, case reports, and reviews that inform best practices and improve patient outcomes. Although EPILEPSIA currently does not offer open access options, its detailed exploration of both fundamental and clinical aspects of epilepsy ensures wide dissemination of crucial findings among professionals and students alike, furthering the understanding and management of this complex condition.

Movement Disorders Clinical Practice, published by WILEY, is an essential peer-reviewed journal dedicated to advancing the understanding and treatment of movement disorders from a clinical perspective. With an ISSN of 2330-1619, this journal serves as a vital resource for researchers, clinicians, and students engaged in neurology and clinical neuroscience. Since its inception in 2014, the journal has established itself within the medical community, currently positioned in the Q2 category for both Neurology and Neurology (Clinical), reflecting its influence and reputation. Although it does not offer open access, the journal is integral for disseminating high-quality research and clinical insights, thereby contributing significantly to improved patient care and outcomes in the field of movement disorders. Based in Hoboken, NJ, it continues to attract contributions from leading experts and aims to foster a deeper understanding and dialogue surrounding contemporary challenges and advancements in movement disorder treatment.

Current Treatment Options in Cardiovascular Medicine is a leading journal dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by SpringerNature, this journal seeks to bridge the gap between clinical practice and research by providing comprehensive reviews, insightful analyses, and updates on the latest treatment modalities available for cardiovascular diseases. With an ISSN of 1092-8464 and an E-ISSN of 1534-3189, it displays a commitment to disseminating critical information to healthcare professionals and researchers globally. Despite its recent categorization in the Q3 quartile, the journal continues to maintain relevance with a Scopus rank of #246 in the field, reflecting its contribution to the ongoing discourse in cardiovascular care. The publication encompasses a broad spectrum of topics, from interventional cardiology to pharmacotherapy, supporting the journal's objective to enhance patient care through evidence-based treatment options. Researchers, professionals, and students will find Current Treatment Options in Cardiovascular Medicine an indispensable resource for staying at the forefront of cardiovascular innovations and applications.

Epilepsy & Behavior Reports, a distinguished journal published by ELSEVIER SCIENCE INC, specializes in the latest research and developments in the field of epilepsy and related behavioral conditions. Since its inception in 2019 as a fully Open Access journal, it has carved a niche for itself within the scientific community, providing an essential platform for researchers and clinicians focused on behavioral neuroscience and neurology. The journal's commitment to disseminating high-quality research is reflected in its current rankings within Scopus, placing it within the Q3 category for Behavioral Neuroscience and Clinical Neurology, underscoring its relevance to emerging trends in these fields. Located in the heart of New York, the journal strives to foster collaboration and innovation, making it a vital resource for academics, practitioners, and students eager to advance their understanding of epilepsy and its behavioral implications. The convergence of expertise and research in Epilepsy & Behavior Reports promises to illuminate crucial aspects of neurological health, driving forward the discourse that shapes future treatment and understanding of epilepsy.

Acta Epileptologica is a prominent open-access journal published by SPRINGERNATURE, dedicated to advancing research in the fields of neurology and clinical neurology. With its ISSN 2096-9384 and E-ISSN 2524-4434, this journal has established itself as a key resource for researchers and practitioners worldwide, particularly since its transition to open access in 2019. Based in the United Kingdom, Acta Epileptologica aims to disseminate high-quality research and foster scholarly collaboration, as evidenced by its consistent Q3 ranking in both neurology and clinical neurology categories as of 2023. Although currently positioned in the lower percentiles on Scopus, the journal plays a critical role in exploring emerging trends and novel therapeutic approaches in epilepsy research, making it an essential platform for academics, healthcare professionals, and students deeply invested in the evolving landscape of neurological disorders.

Einstein-Sao Paulo is a premier open-access journal dedicated to advancing the field of medicine, published by the prestigious INST ISRAELITA ENSINO & PESQUISA ALBERT EINSTEIN in Brazil. Since its inception in 2010, this journal has served as a vital platform for researchers and practitioners alike, fostering the dissemination of groundbreaking studies and innovative healthcare solutions. With an impressive reputation reflected in its Q3 ranking in the category of Medicine (Miscellaneous) and a commendable Scopus rank of #243 out of 636 in general medicine, the journal is positioned as a significant contributor to the global medical research landscape. Its commitment to open access ensures that the latest research is freely available to a wide audience, promoting collaboration and knowledge sharing among professionals. The journal covers a vast array of topics within the medical domain, and its purpose is to bridge the gap between theoretical research and clinical practice, ultimately improving patient care and advancing public health. For researchers, students, and healthcare professionals seeking to stay at the forefront of medical innovation, Einstein-Sao Paulo is an indispensable resource.

Welcome to the Journal of Burn Care & Research, a prominent publication under the esteemed Oxford University Press. With its dedication to advancing the field of burn care, the journal serves as a vital platform for researchers, clinicians, and healthcare professionals to disseminate cutting-edge findings and innovative practices. The journal, bearing the ISSN 1559-047X and E-ISSN 1559-0488, has shown impressive performance, ranking in the Q2 category in multiple fields including Emergency Medicine, Medicine (Miscellaneous), Rehabilitation, and Surgery as of 2023, indicating its significant impact within the academic community. The Scopus rankings further highlight its value, with respectable rankings in specific categories, reinforcing its relevance and reach. The journal aims to foster innovative research and clinical excellence, encouraging Open Access to maximize knowledge sharing and collaboration across disciplines. Established in 2006 and continuing through to 2024, the Journal of Burn Care & Research is your essential resource for high-quality research and reviews that aim to improve outcomes for patients affected by burns and related conditions.

HAEMOPHILIA is a leading peer-reviewed journal published by Wiley, dedicated to advancing research and clinical practices in the fields of hematology and genetics. With an impressive Impact Factor and recognition within the Q1 category for Genetics (clinical), Hematology, and Medicine (miscellaneous), this journal presents a unique platform for the dissemination of high-quality research from 1995 to the present. Researchers in these dynamic fields will find invaluable insights through original articles, systematic reviews, and clinical trials, all aimed at improving therapeutic strategies and patient outcomes. Although it operates on a subscription basis, HAEMOPHILIA's commitment to excellence is reflected in its Scopus rankings, where it stands in the 74th percentile for hematology and the 71st percentile for clinical genetics. As an essential resource for academics, healthcare professionals, and students, HAEMOPHILIA plays a pivotal role in fostering innovation and collaboration within the global medical community.